Silo Pharma (SILO) Stock Price, News & Analysis

Company Overview

Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health.

Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia. Its research portfolio has also included intranasal formulations and other therapeutics targeting disorders such as post-traumatic stress disorder and Alzheimer’s disease. Development programs remain subject to preclinical and clinical evaluation, as applicable.

The company has pursued research and development collaborations with academic and scientific institutions, including work involving novel drug-delivery technologies and psychedelic compounds. Silo Pharma is headquartered in the United States and, as a development-stage company, primarily focuses on advancing its pipeline rather than marketing a broad portfolio of commercial products. Eric Weisblum serves as the company’s chief executive officer.

Key Stats

• Today's Range: $1.76 to $1.92
• 50-Day Range: $1.13 to $2.40
• 52-Week Range: $1.10 to $10.43
• Volume: 48,855 shs
• Average Volume: 39,794 shs
• Market Capitalization: $2.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Silo Pharma Stock Analysis - MarketRank™

Silo Pharma scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Silo Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Silo Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Silo Pharma is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Silo Pharma is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Silo Pharma has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.90% of the float of Silo Pharma has been sold short.

Short Interest Ratio / Days to Cover

Silo Pharma has a short interest ratio ("days to cover") of 1.07, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Silo Pharma has recently decreased by 37.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Silo Pharma does not currently pay a dividend.

Dividend Growth

Silo Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 4.6 / 5
• News Sentiment: 2.39

News Sentiment

Silo Pharma has a news sentiment score of 2.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Silo Pharma this week, compared to 1 article on an average week.

MarketBeat Follows

4 people have added Silo Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Silo Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.63% of the stock of Silo Pharma is held by insiders.

Percentage Held by Institutions

5.58% of the stock of Silo Pharma is held by institutions.

Company Calendar

• Last Earnings: 11/13/2026
• Today: 11/15/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SILO
• CIK: 1514183
• Web: silopharma.com
• Phone: (718) 400-9031
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.23 million
• Net Margins: -6,726.39%
• Pretax Margin: -8,283.33%
• Return on Equity: -81.75%
• Return on Assets: -66.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.36
• Quick Ratio: 5.36

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 41.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.10 per share
• Price / Book: 0.26

Miscellaneous

• Outstanding Shares: 1,590,000
• Free Float: 1,530,000
• Market Cap: $2.93 million
• Optionable: Not Optionable
• Beta: 0.81